Prostate cancer (advanced, hormone dependent) - degarelix depot: notice of appeal
NICE has received three appeals against the Final Appraisal Determination on the above technology from the following organisations:
- Ferring Pharmaceutical Ltd
- British Uro-oncology Group
- Tackle Prostate Cancer
The appeal panel will convene on 25 June 2014 at ETC venues, Prospero House, 241 Borough High Street, London SE1 1GA to hear oral representations from the appellants.
Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of places for observers is constrained by the venue, and priority will be given to members of the public who are not employed by the appellant. There are twenty five places available for this appeal hearing.
Where possible, requests to attend should be made using the form that will be available on the Institute’s web site. This form will be available from 16 May 2014 only. The web site registration will allow requests to attend to be granted on a first-come, first-served basis. The registration period for this appeal will end at 5pm 2 June 2014. Further details relating to public attendance at this appeal are available on the same webpage as above.
A limited number of places at the appeal hearing will be reserved for members of the public who do not have access to the internet. These places should be applied for in writing, addressed to the Appeals Coordinator, to arrive before 5pm on 2 June 2014. Written requests to attend will also be granted on a first-come, first-served basis.
This page was last updated: 05 June 2014